Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub,Uma Borate,Raajit Rampal,Haris Ali,Eunice S Wang,Aaron T Gerds,Gabriela Hobbs,Marina Kremyanskaya,Elliott Winton,Casey O'Connell,Swati Goel,Stephen Oh,Gary J Schiller,Albert Assad,Sue Erickson-Viitanen,Feng Zhou,Naval Daver

doi:10.1182/blood-2021-148668

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate + Show 15 more

Open Access

https://doi.org/10.1182/blood-2021-148668

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 2

Affiliation: University of Kansas Cancer Center, Oregon Health & Science University, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, Roswell Park Cancer Institute, Cleveland Clinic, Massachusetts General Hospital, Icahn School of Medicine at Mount Sinai, Emory University, University of Southern California, Montefiore Medical Center, Washington University in St. Louis, University of California, Los Angeles, Incyte (United States), The University of Texas MD Anderson Cancer Center

#Research Funding #Equity Holder In Publicly-traded Company + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.